This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Opinion: Digging into the current and developing treatment landscape for Nonalcoholic steatohepatitis (NASH)

Ticker(s): ICPT, NVO, MDGL

Who's the expert?

Institution: Washington State University & Liver Institute Northwest

  • Professor of Medicine at Washington State University.
  • Developed murine models for NASH and is currently exploring the contribution of hepatic iron deposition on the severity of NASH.
  • Extensive clinical research interest in all areas of liver disease, ranging from hepatitis C, cholestatic liver disease, PBC, PSC, nonalcoholic steatohepatitis and hepatitis B
  • Has authored more than 400 articles, book chapters, reviews and presented his research on liver diseases at more than 150 national and international meetings and scientific symposia.

Interview Questions

Potential for new drug therapies in this space?

Added By: dami_admin

Please update us on how field has evolved over past few years.

Importance of liver biopsies for clinical trials and how will this impact commercial opportunities

Has imaging improved ?  

Impact of Covid

Added By: dami_admin

Which MOA in development is of the highest interest to you and why?

Added By: dami_admin

Are combination strategies going to be the best way to treat NASH in the future? 

Added By: dami_admin

Clinical trial failures - Many drugs have flopped in recent years. What have we learned

Added By: dami_admin

The GLP-1 agonist Semaglutide had some success and failure in Phase 2 with different stages of disease.  

Please provide your interpretation of these conflicting results and your view on potential of this drug class in NASH

Added By: dami_admin

Background on clinical practice, how many NASH patients do you manage?

Added By: dami_admin

How is NASH currently diagnosed and treated?

Added By: dami_admin

After the failure of elafibranor, do you see lanifibranor as differentiated and what do you view as likelihood of its phase 3 success?

Added By: user1ae2bf5f

Endpoints of NASH resolution vs. improvement in fibrosis, why do so many drugs achieving robust NASH resolution fail on fibrosis improvement?
View of the Madrigal phase 3 trial design that is looking for NASH resolution and longterm hard outcomes instead of fibrosis stage improvement in short term

Added By: user1ae2bf5f

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.